Can a tailored drug cocktail beat lung cancer recurrence?

NCT ID NCT04585490

Recruiting now Disease control Sponsor: Maximilian Diehn Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial is testing whether adding an extra immunotherapy drug (tremelimumab) and more chemotherapy to the standard treatment (durvalumab) can lower the amount of cancer DNA found in the blood of people with stage III non-small cell lung cancer. The study enrolls 48 participants who have already completed chemoradiation and are on durvalumab. The goal is to see if a personalized, more intense treatment can better control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Durvalumab, tremelimumab, carboplatin, pemetrexed, paclitaxel
What this could lead to: If successful, this could lead to a more personalized treatment approach that better controls stage III lung cancer and reduces the risk of recurrence.
What could go wrong: This is a small early-phase trial with only 48 participants, so results may not apply to everyone. Adding more drugs also increases the chance of side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER NSCLC NSCLC, STAGE III

Contacts and locations

Locations

Stanford University
RECRUITING

Stanford, California, 94304, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.